在临床前小鼠模型中开发放射性脑损伤神经炎症、认知障碍与生存结局的磁共振成像生物标志物
研究采用8周龄雌性免疫健全BALB/c小鼠,立体定向单次80 Gy照射后纵向行多参数MRI、行为学与免疫组化检查。鉴定出三类可转化MRI生物标志物:对比增强T1WI反映早期血脑屏障通透性增高,T2WI高信号反映中期损伤,T2WI/T2*WI低信号反映晚期铁沉积。
要点
- 对比增强T1WI在照射后1个月检测血脑屏障通透性最大值,对应神经炎症高峰与短暂认知障碍起始。
- T2WI高信号在照射后2个月达峰值,与星形胶质细胞增生最大值相关,适合检测中期损伤。
- T2WI/T2*WI低信号从照射后4个月出现,与晚期血管损伤所致铁沉积相关,并先于体重下降、严重认知障碍和生存期缩短。
核心结论
- 研究鉴定出三类可转化的RIBI MRI生物标志物,可能实现无创纵向评估潜在RIBI预防和治疗药物,并可能在脑肿瘤幸存者RIBI管理中起关键作用。
研究设计与样本
- 临床前小鼠研究:8周龄雌性免疫健全BALB/c小鼠立体定向单次80 Gy照射(剂量率1.7 Gy/分钟),纵向行多参数MRI、学习记忆行为测试和免疫组化,与未照射小鼠比较。
关键影像表现/征象
- 对比增强T1加权MRI在照射后1个月检测到血脑屏障通透性最大值(18.95 ± 1.75),照射小鼠较未照射小鼠P < 0.0001,n = 3。
- T2加权MRI高信号在照射后2个月检测到最大值(3.97 ± 2.07),照射小鼠较未照射小鼠P = 0.0368,n = 3。
- T2加权和T2*加权MRI低信号从照射后4个月起检测到,与晚期血管损伤所致铁沉积增加相关,经Perls普鲁士蓝组织学验证(P < 0.05,n = 3)。
临床应用与阅片要点
- 对比增强T1WI适合检测RIBI损伤起始,表现为血脑屏障通透性改变,照射后1个月达最大。
- T2WI高信号适合检测中期损伤,照射后2个月达最大,并与星形胶质细胞增生最大值(9.92 ± 4.21,P = 0.0215,n = 3)相关。
- T2WI和T2*WI低信号适合检测晚期损伤(照射后4个月起),与铁沉积相关,并先于体重显著下降、严重认知障碍和生存期缩短出现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Radiotherapy-induced brain injury (RIBI) is a chronic side effect that affects up to 90% of brain tumor survivors treated with radiotherapy. Here, we used multiparametric magnetic resonance imaging (MRI) to identify noninvasive and clinically translatable biomarkers of RIBI.
METHOD: 8-week-old female, immune competent BALB/c mice were stereotactically irradiated with a single dose of 80 Gy, at a dose rate of 1.7 Gy/minute. The irradiated mice were then monitored longitudinally with MRI, behavioral tests of learning and memory, and immunohistochemistry, in comparison to nonirradiated mice.
RESULTS: Three types of MRI biomarkers of RIBI were identified. A contrast-enhanced T 1 -weighted MRI biomarker was identified as being best suited to detect the onset of injury, by detecting changes in the blood-brain barrier (BBB) permeability. Maximum BBB permeability (18.95 ± 1.75) was detected with contrast-enhanced T 1 -weighted MRI at 1-month postirradiation in irradiated mice ( P < 0.0001, n = 3). Interestingly, maximum neuroinflammation (24.14 ± 6.72) was also detected using IBA1 and CD68 immunohistochemistry at 1-month postirradiation in irradiated mice ( P = 0.0041, n = 3). This simultaneous maximum BBB permeability and neuroinflammation detection also coincided with the detection of the onset of transient cognitive impairment, detected using the fear-conditioning behavioral test at 1-month postirradiation in irradiated mice compared to nonirradiated mice ( P = 0.0017, n = 10). A T 2 -weighted MRI hyperintensity biomarker was also identified, and determined to be best suited to detect intermediate injury. Maximum T 2 -weighted MRI hyperintensity (3.97 ± 2.07) was detected at 2-month postirradiation in the irradiated mice compared to nonirradiated mice ( P = 0.0368, n = 3). This T 2 -weighted MRI hyperintensity also correlated with maximum astrogliosis (9.92 ± 4.21), which was also detected at 2-month postirradiation using GFAP immunohistochemistry in the irradiated mice compared to nonirradiated mice ( P = 0.0215, n = 3). Finally, T 2 -weighted and T 2 *-weighted MRI hypointensity biomarkers were identified as being best suited to detect late injury, from 4-month postirradiation. These biomarkers correlated with increased iron deposition from late vascular damage, which was validated with Perls' Prussian blue histology ( P < 0.05, n = 3). These hypointense MRI biomarkers of late injury also preceded significant weight loss, severe cognitive impairment, and decreased survival in the irradiated mice compared to the nonirradiated mice.
CONCLUSIONS: Here, we identified 3 types of translational MRI biomarkers of RIBI that could enable the noninvasive longitudinal evaluation of potential RIBI prophylactic and therapeutic agents. These translational MRI biomarkers could also play a pivotal role in the management of RIBI in brain tumor survivors.
引用
- Teitz M, Velarde E, Yang X, et al. Developing Magnetic Resonance Imaging Biomarkers of Neuroinflammation, Cognitive Impairment, and Survival Outcomes for Radiotherapy-Induced Brain Injury in a Preclinical Mouse Model. Invest Radiol. 2026. PMID: 40095964. doi:10.1097/RLI.0000000000001173
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。